Iovance Biotherapeutics (HAM:2LB) Retained Earnings: €-2,469.2 Mil (As of Mar. 2026)


HAM:2LB Iovance Biotherapeutics Inc HAM:2LB
44 GF Score
Price €3.78
GF Value €17.09
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Retained Earnings?

Iovance Biotherapeutics HAM:2LB +2.44% 44 Retained Earnings is €-2,469.2 Mil as of Mar. 2026. GuruFocus rates HAM:2LB with a GF Score™ of 44/100 and a GF Value™ of €17.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Iovance Biotherapeutics's retained earnings for the quarter that ended in Mar. 2026 was €-2,469.2 Mil.

Iovance Biotherapeutics's quarterly retained earnings declined from Sep. 2025 (€-2,303.5 Mil) to Dec. 2025 (€-2,370.3 Mil) and declined from Dec. 2025 (€-2,370.3 Mil) to Mar. 2026 (€-2,469.2 Mil).

Iovance Biotherapeutics's annual retained earnings declined from Dec. 2023 (€-1,845.3 Mil) to Dec. 2024 (€-2,277.2 Mil) and declined from Dec. 2024 (€-2,277.2 Mil) to Dec. 2025 (€-2,370.3 Mil).


Iovance Biotherapeutics  (HAM:2LB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Iovance Biotherapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Retained Earnings Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,037.61 -1,480.51 -1,845.35 -2,277.25 -2,370.30

Iovance Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,313.16 -2,264.93 -2,303.49 -2,370.30 -2,469.21
HAM:2LB
44GF Score
Iovance Biotherapeutics Inc HAM:2LB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-2,469.2 Mil mean?
Iovance Biotherapeutics (HAM:2LB) has a Retained Earnings of €-2,469.2 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Retained Earnings too high?
Iovance Biotherapeutics' current Retained Earnings is €-2,469.2 Mil. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Retained Earnings compare to SNDX and GLUE?
Iovance Biotherapeutics' Retained Earnings of €-2,469.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Retained Earnings is €-2,469.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (HAM:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €17.09, compared to a current price of €3.78 — trading 77.9% below its estimated fair value. The current Retained Earnings is €-2,469.2 Mil. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Iovance Biotherapeutics (HAM:2LB), the current Retained Earnings is €-2,469.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (HAM:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €3.78 is trading 77.9% below its estimated GF Value™ of €17.09. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for HAM:2LB:

  • Retained Earnings: €-2,469.2 Mil
  • GF Value™: €17.09 vs. price of €3.78 (77.9% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the HAM:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for HAM:2LB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.78
Price
€17.09
GF Value